Publications des scientifiques de l'IRD

Pion S. D. S., Gardon J., Kamgno J., Gardon Wendel N., Chippaux J. P., Boussinesq M.. (2004). Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the programmes of Community-Directed Treatment with Ivermectin carried out in Africa. Parasitology, 129 Part 5, p. 613-626. ISSN 0031-1820.

Titre du document
Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the programmes of Community-Directed Treatment with Ivermectin carried out in Africa
Année de publication
2004
Type de document
Article référencé dans le Web of Science WOS:000225172700010
Auteurs
Pion S. D. S., Gardon J., Kamgno J., Gardon Wendel N., Chippaux J. P., Boussinesq M.
Source
Parasitology, 2004, 129 Part 5, p. 613-626 ISSN 0031-1820
This paper describes the structure of the microfilarial reservoir of Loa loa in an endemic population of central Cameroon. The possible effects of age and sex on the prevalence and intensity of microfilaraemia have been explored. Logistic analysis showed that the prevalence of microfilaraemia increased significantly with age, reaching 60% in the oldest males. This result suggests that the figure commonly reported, according to which only one third of the infected individuals were microfilaraemic, should be reconsidered; in addition, as part of surveys of loiasis, crude microfilaraemia prevalence values should be replaced by adjusted ones. The intensity of infection did not show any age-specific change. As a result, even if the oldest members of the male population are clearly the most at risk of developing post-ivermectin serious adverse reactions, especially Loa-encephalopathy, the other members of the population are not risk-free. Therefore, in those areas where the African Programme for Onchocerciasis Control is undertaking regular mass distributions of ivermectin for onchocerciasis control, and where loiasis is co-endemic, no subpopulation should be excluded from surveillance and monitoring during community directed treatments with ivermectin.
Identifiant IRD
PAR00000041
Contact